Thyroid hormone state and quality of life at long-term follow-up after randomized treatment of Graves' disease

European Journal of Endocrinology

Volumn 156, Issue 2, 2007, Pages 173-179

  Abraham Nordling, Mirna ^a   Wallin, Göran ^a   Lundell, Göran ^a   Törring, Ove ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; THYROID HORMONE; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; AUTOANTIBODY; IODIDE PEROXIDASE; RADIOACTIVE IODINE; THYROTROPIN RECEPTOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GRAVES DISEASE; HEALTH STATUS; HUMAN; LIOTHYRONINE BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SWEDEN; THYROID HORMONE BLOOD LEVEL; THYROID SURGERY; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; AGED; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; STATISTICAL MODEL; THYROIDECTOMY; TREATMENT OUTCOME;

AGED; AUTOANTIBODIES; FEMALE; FOLLOW-UP STUDIES; GRAVES DISEASE; HEALTH STATUS; HUMANS; IODIDE PEROXIDASE; IODINE RADIOISOTOPES; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, THYROTROPIN; THYROID HORMONES; THYROIDECTOMY; THYROTROPIN; THYROXINE; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 33947723721     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02336     Document Type: Article

References (16)

1. Fahrenfort JJ, Wilterdink AM & van der Veen EA. Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism. Psychoneuroendocrinology 2000 25 201-211.
2. Elberling TV, Rasmussen AK, Feldt-Rasmussen U, Hording M, Perrild H & Waldemar G. Impaired health-related quality of life in Graves' disease. A prospective study. European Journal of Endocrinology 2004 151 549-555,
3. Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF & Wiersinga WM. Quality of life in patients with Graves' ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid 1997 7 885-889.
4. Kahaly GJ, Hardt J, Petrab F & Egle UT. Psychosocial factors in subjects with thyroid-associated ophthalmopathy. Thyroid 2002 12 237-239.
5. Terwee C, Wakelkamp I, Tan S, Dekker F, Prummel MF & Wiersinga W. Long-term effects of Graves' ophthalmopathy on health-related quality of life. European Journal of Endocrinology 2002 146 751-757.
6. Watt T, Groenvold M, Rasmussen ÅK, Bonnema SJ, Hegedüs L, Bjorner JB & Feldt-Rasmussen U. Quality of life in patients with benign thyroid disorders. A review. European Journal of Endocrinology 2005 154 501-510.
7. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H & Taube A. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. New England Journal of Medicine 1992 326 1733-1738.
8. Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, Saaf M & Hamberger B. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine - a prospective, randomized study. Thyroid Study Group. Journal of Clinical Endocrinology and Metabolism 1996 81 2986-2993.
9. Ljunggren JG, Torring O, Wallin G, Taube A, Tallstedt L, Hamberger B & Lundell G. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 1998 8 653-659.
10. Abraham-Nordling M, Torring O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J & Wallin G. Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 2005 11 1279-1286.
11. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S & Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. European Journal of Endocrinology 2005 152 1-9.
12. Ware JE Jr & Sherbourne CD. The MOS 3 6-item short-form health survey (SF-36) I. Conceptual framework and item selection. Medical Care 1992 30 473-483.
13. Persson LO, Karlsson J, Bengtsson C, Steen B & Sullivan M.The Swedish SF-36 health survey II. Evaluation of clinical validity: results from population studies of elderly and women in Gothenborg. Journal of Clinical Epidemiology 1998 51 1095-1103.
14. Sullivan M, Karlsson J & Ware JE Jr. The Swedish SF-36 health survey- I. Evaluation of data quality,scaling assumptions, reliability and construct validity across general populations in Sweden. Social Science and Medicine 1995 41 1349-1358.
15. Sullivan M & Karlsson J. The Swedish SF-36 health survey III. Evaluation of criterion-based validity: results from normative population. Journal of Clinical Epidemiology 1998 51 1105-1113.
16. Bollerslev J, Jansson S, Mollerup CL, Nordenstrom J, Lundgren E, Torring O, Varhaug EJ, Isaksen AG & Rosen T. The Scandinavian investigation of primary hyperparathyroidism: end of inclusion & preliminary results. Endocrine Abstracts 2006 11 OC56.